Beacon Therapeutics Holdings Limited, an ophthalmic gene therapy company specializing in retinal diseases, has secured $170 million in Series B funding. The financing round was led by life sciences venture capital firm Forbion, with participation from existing investors Syncona, Oxford Science Enterprises, and new investors TCGX and Advent Life Sciences. The capital will accelerate the clinical development of Beacon’s lead asset, AGTC-501, a gene therapy targeting X-Linked Retinitis Pigmentosa (XLRP), and support its dry age-related macular degeneration (dAMD) program. As part of the funding arrangement, Beacon has appointed Dmitrij Hristodorov and Wouter Joustra from Forbion, and Cariad Chester from TCGX, to its Board of Directors, along with Dominic Schmidt from Advent Life Sciences as a Board Observer. The raised funds will bolster Beacon’s pipeline and contribute towards its commercial aspirations in gene therapies for prevalent and rare retinal diseases.

Biotechnology, Healthcare, Venture Capital,United Kingdom, United States

Beacon Therapeutics Raises $170 Million in Series B Funding to Advance Development of Ophthalmic Gene Therapies